Welcome to our dedicated page for Goodrx Holdings SEC filings (Ticker: GDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoodRx Holdings, Inc. (NASDAQ: GDRX) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a digital healthcare and medication savings platform. These SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with exhibits covering executive compensation, director arrangements, and key commercial developments.
In its earnings-related Form 8-K filings, GoodRx furnishes press releases that discuss revenue from prescription transactions, subscriptions, and pharma manufacturer solutions, as well as non-GAAP metrics such as Adjusted EBITDA and Adjusted Net Income. These documents also describe capital allocation priorities, including investing for growth, debt repayment, share repurchases, and mergers and acquisitions that align with the company’s strategy.
Other 8-K filings provide detail on governance and compensation matters. For example, GoodRx has reported retention bonus agreements for certain executives, including the structure of cash retention bonuses and repayment conditions tied to employment status. It has also disclosed the transition of an executive officer to a non-employee director role, outlining standard non-employee director compensation, committee retainers, and restricted stock unit awards under its non-employee director compensation program and deferred compensation plan.
Through this page, users can access GoodRx’s SEC filings as they are made available via EDGAR. AI-powered summaries on the platform help explain the contents of complex documents, including 10-K and 10-Q reports, by highlighting key themes such as segment performance, prescription transactions trends, subscription and pharma manufacturer solutions growth, and risk factor disclosures. Filings related to insider and director compensation, as well as current reports on material events, are also accessible, giving investors and researchers a structured view of how GoodRx manages its business, governance, and financial reporting obligations.